http://www.gastrojournal.org/article/S0016-5085(16)34971-X/abstra...

http://www.gastrojournal.org/articl...hl=en&as_sdt=0,5&q=radioembolization&scisbd=1

Apologies if this has been posted before.  Does this augur well for SARAH?  I am confused and perhaps a little concerned about the last sentence re survival - does not seem to tie up with the promising TTP data.  Any clues?

Results

Patients in the Y90 radioembolization group had significant longer median TTP (>26 months) than patients in the cTACE group (6.8 months) (P=.0012) (hazard ratio=0.122; 95% CI, 0.027–0.557; P=.007). This was confirmed by competing risk and inverse probability of censoring weighting analyses accounting for transplantation or death. A significantly greater proportion of patients in the cTACE group developed diarrhea (21%) than in the Y90 group (0%; P=.031) or hypoalbuminemia (58% in the cTACE group vs 4% in the Y90 group) (P<.001). Similar proportions of patients in each group had a response to therapy, marked by necrosis (74% in the cTACE group vs 87% in the Y90 group) (P=.433). Median survival time, censored to liver transplantation, was 17.7 months for the cTACE group (95% CI, 8.3–NC) vs 18.6 months for the Y90 group (95% CI, 7.4–32.5) (P=.99).